Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, speaks with Stephen Johnston, CEO, Calviri, about the shift in the I-O space to preventative treatment in combination for early-stage cancers.
No takes yet. Share an insight, caveat, or question.
Stephen J. Johnston (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: